ASH 2020 | Analysis of long-term exposure to momelotinib in the Phase III SIMPLFY myelofibrosis trials
Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares long-term outcome data from the Phase III SIMPLIFY trials (S1, NCT01969838; S2, NCT02101268) of momelotinib therapy in intermediate- or high-risk myelofibrosis (MF) patients. S1 and S2 compared momelotinib, a JAK1/2 and ACVR1 inhibitor, to ruxolitinib or best available therapy (BAT), followed by continued momelotinib therapy in both arms after the randomized treatment period. Overall, the benefits of momelotinib appear robust and durable in this analysis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
